Key Inclusion Criteria:  - Male or non-pregnant female with: A. Symptomatic ambulatory male or non-pregnant female adult ≥ 18 years of age at time of enrolment with mild COVID-19 with score 2 or 3 of the 10-score WHO clinical progression scale OR B. Hospitalized male or non-pregnant female adult ≥ 18 years of age at time of enrolment with COVID-19 with score 4 or 5 of the 10-score WHO clinical progression scale.  Symptoms consistent with COVID-19, as determined by investigator, with onset ≤5 days before randomization Positive test for COVID-19 ≤72 hours prior to randomization Negative test for the IgG anti-SARS-CoV-2  Key Exclusion Criteria:  Any use of anti-viral medications up to 7 days before participating in the study Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) any time before participating in the study Receipt of last recommended dose of a SARS-CoV-2 vaccine up to 30 days before participating in the study Receipt of a monoclonal antibodies up to 30 days before participating in the study.  Other protocol-defined inclusion/exclusion criteria may apply